Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. You look at survival for patients with ...

SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Joseph Mikhael, MD ...

People who develop this blood cancer before their sixties are likely to experience the condition in dramatically different ways. Fifteen years ago, Yolanda Brunson-Sarrabo was in her thirties and ...